Research Summary

I am a physician-scientist experienced in clinical and translational laboratory efforts to understand and improve upon cancer immunotherapies.

Clinically, I see patients in the Cancer Immunotherapy Program where I am an attending physician, principal investigator, and co-investigator on early-phase/first-in-human trials testing novel immunotherapies in advanced solid tumors, with a particular focus on genitourinary malignancies. This includes high-risk modalities such as bispecific T cell engaging therapies, immune agonist antibodies, intratumoral immunotherapy, and adoptive cell therapies.

In the laboratory, I study samples from prostate and bladder cancer patients treated with immunotherapy using unbiased platforms such as single-cell RNA sequencing and T cell receptor sequencing. The goal of this work is to discover and validate novel T cell populations and antigenic specificities that are responsible for anti-tumor efficacy as well as immune-related adverse events (IRAEs) resulting from treatment.

Research Funding

  • March 1, 2019 - February 29, 2024 - Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events, Principal Investigator. Sponsor: NIH/NIAID, Sponsor Award ID: K08AI139375
  • March 1, 2019 - February 29, 2024 - Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events, Principal Investigator. Sponsor: NIH/NIAID, Sponsor Award ID: K08AI139375
  • March 1, 2019 - February 29, 2024 - Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events, Principal Investigator. Sponsor: NIH/NIAID, Sponsor Award ID: K08AI139375

Education

Harvard College, Cambridge, MA, AB, 06/2000, Biochemical Sciences
Stanford University School of Medicine, Stanford, CA, MD, 06/2011, Medicine
Stanford University School of Medicine, Stanford, CA, PhD, 06/2011, Molecular and Cellular Physiology
University of California, San Francisco, CA, Residency, 06/2014, Internal Medicine
University of California, San Francisco, CA, Fellowship, 06/2017, Hematology/Oncology

Honors & Awards

  • 9/2001-6/2011
    Medical Scientist Training Program awardee
  • 3/2010
    Keystone Symposia Travel Scholarship
  • 6/2015
    UCSF Hematology/Oncology Clinical Fellow Award (selected by Medicine housestaff for patient care, teaching, professionalism)
  • 1/2016
    UCSF Hematology/Oncology 2016 Award for Excellence in Fellowship Research
  • 4/2016
    Merit Award, Conquer Cancer Foundation of American Society of Clinical Oncology
  • 6/2017
    Young Investigator Award, Conquer Cancer Foundation of American Society of Clinical Oncology
  • 5/2018
    Young Investigator Award, Bladder Cancer Advocacy Network
  • 7/2018
    Young Investigator Award, Prostate Cancer Foundation

Selected Publications

  1. Naidus E, Bouquet J, Oh DY, Looney TJ, Yang H, Fong L, Standifer NE, Zhang L Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients.  View on PubMed
  2. Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig M, Gleave M, Evans CP, Lara P, Chi KN, Reiter RE, Alumkal JJ, Ashworth A, Aggarwal R, Small EJ, Daugherty PS, Ribas A, Oh DY, Shon JC, Feng FY Autoantibody Landscape in Patients with Advanced Prostate Cancer.  View on PubMed
  3. Zhang L, Kandadi H, Yang H, Cham J, He T, Oh DY, Sheikh NA, Fong L Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T.  View on PubMed
  4. Wei J, Wang YH, Lee CY, Truillet C, Oh DY, Xu Y, Ruggero D, Flavell RR, VanBrocklin HF, Seo Y, Craik CS, Fong L, Wang CI, Evans MJ An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers.  View on PubMed
  5. Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer.  View on PubMed
  6. Cham J, Zhang L, Kwek S, Paciorek A, He T, Fong G, Oh DY, Fong L Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies.  View on PubMed
  7. Errol James Philip, Francis Wright, Daniel Myung Kim, Daniel Kwon, Hansen Ho, Son Ho, Edna Cheung, Emily Chan, Sima P. Porten, Anthony C. Wong, Hala Borno, Arpita Desai, Jonathan Chou, David Yoonsuk Oh, Rahul Raj Aggarwal, Lawrence Fong, Eric Jay Small, Terence W. Friedlander, Vadim S Koshkin Efficacy of immune checkpoint inhibitors (ICIs) in rare histological variants of bladder cancer.  View on PubMed
  8. Daniel Kwon, Francis Wright, Li Zhang, Jonathan Chou, Hala Borno, Arpita Desai, David Yoonsuk Oh, YaoYao Guan Pollock, Rohit Bose, Franklin W. Huang, Thomas Hope, Terence W. Friedlander, Lawrence Fong, Felix Y Feng, Eric Jay Small, Rahul Raj Aggarwal, Vadim S Koshkin Treatment outcomes in metastatic prostate cancer patients with DNA damage repair mutations.  View on PubMed
  9. Looney TJ, Topacio-Hall D, Lowman G, Conroy J, Morrison C, Oh D, Fong L, Zhang L TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer.  View on PubMed
  10. Hammami MB, Gill R, Thiruvengadam N, Oh DY, Beck K, Mahadevan U, Kattah MG Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin.  View on PubMed
  11. Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R, Jayaprakash A, Lin I, Casbon AJ, Kinsbury GA, Fong L Clonal Deletion of Tumor-Specific T Cells by Interferon-? Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.  View on PubMed
  12. Oh DY, Fong L Immunity in the Time of Metastases.  View on PubMed
  13. Hagihara K, Chan S, Zhang L, Oh DY, Wei XX, Simko J, Fong L Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer.  View on PubMed
  14. Oh DY,* Cham J,* Zhang L, Fong G, Kwek SS, Klinger M, Faham M, Fong L. *co-first author. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire  View on PubMed
  15. David Yoonsuk Oh, Jason Cham, Li Zhang, Grant Fong, Mark Klinger, Malek Faham, Lawrence Fong Association between T cell repertoire diversification and both clinical response as well as toxicity following immune checkpoint blockade in metastatic cancer patients.  View on PubMed
  16. Oh DY, Venook AP, Fong L On the Verge: Immunotherapy for Colorectal Carcinoma.  View on PubMed
  17. Ehrlich LI,* Oh DY,* Weissman IL, Lewis RS. *co-first author. Differential contribution of chemotaxis and substrate restriction to segregation of immature and mature thymocytes  View on PubMed
  18. Bhakta NR, Oh DY, Lewis RS Calcium oscillations regulate thymocyte motility during positive selection in the three-dimensional thymic environment.  View on PubMed
  19. Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor.  View on PubMed
  20. Beresford PJ, Zhang D, Oh DY, Fan Z, Greer EL, Russo ML, Jaju M, Lieberman J Granzyme A activates an endoplasmic reticulum-associated caspase-independent nuclease to induce single-stranded DNA nicks.  View on PubMed

Go to UCSF Profiles, powered by CTSI